Lantheus Holdings, Inc.(LNTH) Stock Research - Grey Stern Research

Lantheus Holdings, Inc. (LNTH) Stock Analysis

$108.56 (0.39%)

LNTH Financial Performance


Use the table below to view Lantheus Holdings, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $108.14 -
52 Week Low $50.20 -
52 Week High $126.89 -
Market Cap $7.5 Billion 4/15
Gross Margin 65% 9/15
Profit Margin 16% 3/15
EBITDA margin 30% 3/15
Q2 - 2024 Revenue $394.1 Million 4/15
Q2 - 2024 Earnings $62.1 Million 3/15
Q2 - 2024 Free Cash Flow $73.5 Million 2/15
Trailing 4 Quarters Revenue $1.4 Billion 5/15
Trailing 4 Quarters Earnings $428.5 Million 2/15
Quarterly Earnings Growth -34% 12/15
Annual Earnings Growth 400% 1/15
Quarterly Revenue Growth 23% 6/15
Annual Revenue Growth 17% 9/15
Cash On Hand $757.0 Million 1/15
Short Term Debt $3.0 Million 12/15
Long Term Debt $562.8 Million 5/15

Lantheus Holdings, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Lantheus Holdings, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 17.52 6/15
PS 5.22 7/15
PB 7.31 3/15
PC 9.92 8/15
Liabilities to Equity 0.89 7/15
ROA 0.22 1/15
ROE 0.42 3/15
Current Ratio 2.12 7/15
Quick Ratio 0.83 5/15
Long Term Debt to Equity 0.55 7/15
Debt to Equity 0.60 7/15
Burn Rate -19.50 14/15
Cash to Cap 0.10 8/15
CCR 1.18 8/15
EV to EBITDA 62.76 6/15
EV to Revenue 5.13 6/15

Company Details

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

CEO: Ms. Mary Heino

Website: https://www.lantheus.com

Address: 331 Treble Cove Rd North Billerica, MASSACHUSETTS

Exchange: NASDAQ Global Market

Industry: Diagnostics & Research

Lantheus Holdings, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Lantheus Holdings, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Dynavax Technologies Corporation DVAX $1.5 Billion
Pacira BioSciences, Inc. PCRX $677.6 Million
Neurocrine Biosciences, Inc. NBIX $12.2 Billion
Ironwood Pharmaceuticals, Inc. IRWD $720.4 Million
Collegium Pharmaceutical, Inc. COLL $1.3 Billion
Avadel Pharmaceuticals plc AVDL $1.3 Billion
Catalent, Inc. CTLT $10.9 Billion
Alkermes plc ALKS $4.7 Billion
Dr. Reddy's Laboratories Limited RDY $13.1 Billion
ANI Pharmaceuticals, Inc. ANIP $1.3 Billion
Amphastar Pharmaceuticals, Inc. AMPH $2.4 Billion
Deciphera Pharmaceuticals, Inc. DCPH $2.2 Billion
Aquestive Therapeutics, Inc. AQST $473.5 Million
Journey Medical Corporation DERM $105.3 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
LNTH Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 394.1 Million $62.1 Million
Q1 2024 $ 370.0 Million $131.1 Million
Q4 2023 $ 354.0 Million $103.4 Million
Q3 2023 $ 319.9 Million $132.0 Million
Q2 2023 $ 321.7 Million $94.1 Million
Q1 2023 $ 300.8 Million -$2.8 Million
Q4 2022 $ 263.2 Million -$119.2 Million
Q3 2022 $ 239.3 Million $61.2 Million

View All

LNTH Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $757.0 Million $1.9 Billion $620.3 Million $1.0 Billion
Q1 2024 $718.3 Million $1.8 Billion $563.2 Million $945.5 Million
Q4 2023 $713.7 Million $1.7 Billion $616.9 Million $815.9 Million
Q3 2023 $614.1 Million $1.5 Billion $615.7 Million $698.8 Million
Q2 2023 $414.1 Million $1.3 Billion $590.9 Million $552.6 Million
Q1 2023 $470.9 Million $1.3 Billion $559.0 Million $445.5 Million
Q4 2022 $415.7 Million $1.3 Billion $558.1 Million $447.1 Million
Q3 2022 $257.3 Million $1.1 Billion $167.4 Million $638.1 Million

View All

LNTH Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 $73.5 Million -$11.2 Million $38.7 Million
Q1 2024 $119.0 Million -$8.3 Million $4.6 Million
Q4 2023 $100.2 Million -$12.1 Million $99.5 Million
Q3 2023 $102.1 Million -$14.6 Million $200.1 Million
Q2 2023 -$43.0 Million -$10.7 Million -$56.8 Million
Q1 2023 $99.3 Million -$9.2 Million $55.2 Million
Q4 2022 $100.6 Million -$4.7 Million $158.4 Million
Q3 2022 $12.2 Million $1.4 Million $0

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions